Technology Appraisal no 174; Chronic lymphocytic leukaemia (first line) – rituximab and no 193; Chronic lymphocytic leukaemia  (relapsed) – rituximab

Decision to defer the review

As you may be aware the planned date for review of the above guidance was December 2010.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

At the time of publication it was our intention to consider both TA174 and TA193 for review upon the results of the ongoing trial MO20927. The conclusions of this trial will not be made available until the end of 2011.

Consequently Guidance Executive has decided that the consideration to review the original guidance will be deferred until 2012. At this point the evidence base will again be assessed to ascertain the need for a review of the guidance.

December 2010